MX2021006778A - Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. - Google Patents

Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.

Info

Publication number
MX2021006778A
MX2021006778A MX2021006778A MX2021006778A MX2021006778A MX 2021006778 A MX2021006778 A MX 2021006778A MX 2021006778 A MX2021006778 A MX 2021006778A MX 2021006778 A MX2021006778 A MX 2021006778A MX 2021006778 A MX2021006778 A MX 2021006778A
Authority
MX
Mexico
Prior art keywords
cancer
immunomodulation
treatment
novel method
talabostat
Prior art date
Application number
MX2021006778A
Other languages
English (en)
Spanish (es)
Inventor
Vincent J O''neill
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of MX2021006778A publication Critical patent/MX2021006778A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2021006778A 2018-12-10 2019-12-10 Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. MX2021006778A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777352P 2018-12-10 2018-12-10
US201962924429P 2019-10-22 2019-10-22
PCT/US2019/065465 WO2020123496A1 (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Publications (1)

Publication Number Publication Date
MX2021006778A true MX2021006778A (es) 2021-07-15

Family

ID=71075816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006778A MX2021006778A (es) 2018-12-10 2019-12-10 Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.

Country Status (13)

Country Link
US (1) US20220089733A1 (https=)
EP (1) EP3893869A4 (https=)
JP (2) JP2022512158A (https=)
KR (1) KR20210102259A (https=)
CN (1) CN113260361A (https=)
AU (1) AU2019396206A1 (https=)
BR (1) BR112021011205A2 (https=)
CA (1) CA3121270A1 (https=)
IL (1) IL283742A (https=)
MX (1) MX2021006778A (https=)
SG (1) SG11202106129RA (https=)
TW (1) TW202034955A (https=)
WO (1) WO2020123496A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2021158884A1 (en) * 2020-02-07 2021-08-12 Bioxcel Therapeutics, Inc. Treatment regimen for cancer using immunomodulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033368A2 (en) * 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
CA2973040A1 (en) * 2015-01-09 2016-07-14 Mabimmune Diagnostics Ag Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2017058881A1 (en) * 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
US11613785B2 (en) * 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法

Also Published As

Publication number Publication date
JP2025156353A (ja) 2025-10-14
KR20210102259A (ko) 2021-08-19
EP3893869A1 (en) 2021-10-20
TW202034955A (zh) 2020-10-01
JP2022512158A (ja) 2022-02-02
WO2020123496A1 (en) 2020-06-18
CN113260361A (zh) 2021-08-13
BR112021011205A2 (pt) 2021-08-24
EP3893869A4 (en) 2022-08-17
SG11202106129RA (en) 2021-07-29
IL283742A (en) 2021-07-29
US20220089733A1 (en) 2022-03-24
AU2019396206A1 (en) 2021-06-17
CA3121270A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2021000609A (es) Métodos de tratamiento con fármacos sustrato para cyp3a4.
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
MX376193B (es) Compuestos para tratar el cancer cerebral.
MX373231B (es) Agente anticancerigeno.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX364705B (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX387283B (es) Tratamiento del cancer con tg02.
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
EA201890812A1 (ru) Дополнительная терапия 25-гидроксивитамином d и изделия для этого
EA201790332A1 (ru) Дополнительная терапия 25-гидроксивитамином d
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MX388722B (es) Compuestos para tratar el cancer de ovario.
MX2020001727A (es) Terapia de combinacion.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021008972A (es) Terapia de combinacion de quelante metalico para el tratamiento del cancer.
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
MX2021006778A (es) Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.
MX2019003751A (es) Proteina terapeutica.
MX2018012392A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.